Myasthenia Gravis Treatment Market is poised to register a CAGR of 7.5% during the forecast period 2022 to 2028.

The global Myasthenia Gravis Treatment market is expanding rapidly and will continue to expand in the coming years. Myasthenia gravis is a condition that causes the skeletal muscles of the body to weaken. In myasthenia gravis, the immune system impairs nerve impulse transmission to muscles by generating antibodies that attach to proteins involved in nerve signal transmission. Normally, antibodies attach to particular foreign particles and bacteria, designating them for destruction, but in myasthenia gravis, the antibody assaults a normal human protein. In most cases, the antibody attacks a protein called acetylcholine receptor (AChR), whereas in others, the antibodies hit a protein called muscle-specific kinase (MuSK). In both circumstances, the aberrant antibodies reduce the amount of AChR that is accessible.

Consistent R&D activities are projected to drive the growth of the myasthenia gravis therapy market. For example, Alexion Pharmaceuticals, Inc. got FDA clearance for Soliris, a drug that contains eculizumab as an active ingredient. This medication is used to treat antibody-positive generalised myasthenia gravis, as well as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Furthermore, the growing number of clinical studies for the treatment of myasthenia gravis is likely to fuel the growth of the myasthenia gravis treatment market. Novartis AG, for example, has begun a phase II clinical study of CFZ533 for the treatment of severe myasthenia gravis. The primary function of CFZ533 is to modify immunological response by deactivating white blood cells. As a result, it is intended to aid in the treatment and management of severe myasthenia gravis.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Myasthenia Gravis Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Myasthenia Gravis Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Myasthenia Gravis Treatment Market:
• AbbVie, Inc.
• Alexion Pharmaceutical, Inc.
• Amneal Pharmaceuticals, Inc.
• Argenx SE
• Astellas Pharma, Inc.
• Avadel Pharmaceuticals PLC
• Bausch Health Companies Inc.
• Baxter International, Inc.
• CSL Behring
• CuraVac, Inc.
• F. Hoffmann-La Roche, Ltd.
• GlaxoSmithKline plc
• Grifols SA
• Immunovant, Inc.
• Mitsubishi Tanabe Pharma Corp.
• Novartis AG
• RA Pharmaceuticals, Inc.
• Takeda Pharmaceutical Co., Ltd.
• UCB Pharma
• Valeant Pharmaceuticals International, Inc.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Myasthenia Gravis Treatment Market Segmentation:
By Drug Class
• Cholinesterase Inhibitors
• Corticosteroids
• Immunosuppressants
• Other Drug Classes
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Platform
By Region
• North America
• Asia-Pacific
• Latin America
• Middle East and Africa

Myasthenia Gravis Treatment Market Video Sample:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Myasthenia Gravis Treatment Market By Drug Class, By Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com


Need Assistance


UK : +44 141 628 9353
US : +1 347 709 4931


Contact Sales

What you get

  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included

  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics